191 results about "Pulmonary infection" patented technology

A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal / complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Pharmaceutical compositions are described containing carrier particles bearing microparticles of a drug. The drug microparticles may be deposited on the carrier particles, for example, by sublimation. Preferred embodiments of these pharmaceutical compositions are suitable for administration by inhalation or injection. Methods for treating lung infection in patients with cystic fibrosis through inhalation of, for example, calcitriol compositions, are also described.

The invention relates to an inhalation spray of antivirus medicines. The inhalation spray comprises the following components in percentage by mass of 0%-30% of antivirus activity agents, 0%-30% of auxiliary agents, 0%-30% of taste masking agents and the balance solvents, wherein the content of the antivirus activity agents and the content of the auxiliary agents are not 0% at the same time. Compared with the prior art, the inhalation spray disclosed by the application has the purpose that during outbreak period of epidemic corona viruses and other viruses, people do not need to occupy medicalresources in short supply and only need to inhale the antivirus medicines into respiratory tracts, medicine administration is accurately targeted, and the objective of preventing virus infection and propagation can be achieved; in addition, through united medication of the antivirus activity agents and the auxiliary agents, besides, various medicines are inhaled into the respiratory tract of a patient, synergistic treatment effects are generated, the viruses are eliminated, and serious respiratory tract and infection and serious pulmonary infection caused by the viruses can be treated; and chloroquine type antivirus medicines and macrocyclic antibiotics are inhaled through spraying for united medication, and the dosage of the medicines can be notably reduced, so that side effects of prolonged QT intervals, Tdp and sudden cardiac death caused by the medicines can be reduced.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.

The present invention provides carbapenems to treat or prevent pulmonary infections, particularly in patients with cystic fibrosis, pneumonia, ventilator associated pneumonia, bronchitis or bronchiectstasis, pharmaceutical compositions of these carbapenems and methods of administering these carbapenems to treat or prevent pulmonary infections.

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention discloses a prediction model for pulmonary infection after cardiac surgery and a construction method thereof. The method comprises the following steps: screening out evaluation indexes related to pulmonary infection after cardiac surgery from various clinical data of a cardiac surgery patient in a perioperative period; bringing the evaluation indexes into a Logistic regression modelto analyze, calculate and determine regression coefficients of risk factors of pulmonary infection after cardiac surgery; obtaining a risk score through the regression coefficient of each risk factor;and finally, combining the risk score with a pulmonary infection risk prediction function to calculate a pulmonary infection probability value, so that a risk prediction model based on a scoring system can be established. The prediction model disclosed by the invention is good in fitting, shows better risk prediction capability compared with the existing foreign model, can achieve the purpose ofearly screening postoperative pulmonary infection high-risk patients, and plays a role in early prevention, early discovery and early treatment, thereby reducing the incidence rate of postoperative pulmonary infection of the heart.

The invention relates to a medicament for treating pediatric respiratory tract infection and pulmonary infection, which is prepared from campanumaea pilosula, giant knotweed, whiteflower hogfennel root, almond, pummelo peel, willowleaf swallowwort rhizome, indigowoad root, Ningpo yam rhizome, paniculate swallowwort root, Indian trum etflower seed, Chinese magnoliavine fruit, unibract fritillary bulb, pinellia tuber and the like. The medicament has the effects of resisting inflammation, resisting viruses, and relieving cough and asthma, and is used for treating diseases such as acute upper respiratory tract infection (cold and fever), pediatric pneumonia, bronchitis, chronic recurrent trachitis, pulmonary infection, whooping cough and the like. The medicament takes the giant knotweed and the indigowoad root for clearing heat and detoxicating, and cooling blood and disinhibiting throat, the whiteflower hogfennel root for dispelling wind heat of lungs, the almond, the pummelo peel, the willowleaf swallowwort rhizome, the pinellia tuber and the unibract fritillary bulb for eliminating phlegm and relieving cough, the paniculate swallowwort root, the Indian trum etflower seed and the Ningpo yam rhizome for clearing heat and disinhibiting dampness, resisting inflammation, relieving cough, resisting allergic reaction and resisting allergy, and the campanumaea pilosula for tonifying center vitality, strengthening spleen and tonifying lung, supporting right and expelling evil, relieving cough, improving immunity of patients, diffusing lung vitality and clearing phlegm and heat. Medicinal materials such as tatarian aster root and platycodon root are added into the medicament on the basis of the compatibility so as to add the effects of eliminating phlegm and preventing asthma.

In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.

The invention provides a synthetic polypeptide composition for novel coronavirus immunodetection. The synthetic polypeptide composition contains four synthetic polypeptides, the synthetic polypeptidedisclosed by the invention can react with an antibody IgG / IgM of a novel coronavirus (2019-nCoV), does not react with other pulmonary infectious coronaviruses and the like, and does not react with serum of a normal person; the synthetic polypeptide disclosed by the invention is used for detecting a novel coronavirus (2019-nCoV) IgM / IgG antibody in serum, the sensitivity can reach 90% or above, thespecificity can reach 99% or above, and the polypeptide can be obtained through chemical synthesis, does not need to be recombined through a biotechnology, and is lower in cost, easier to obtain andconvenient to apply and popularize.

Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (− / −) mice. The SP-D (− / −) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (− / −) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.

The invention discloses a method for detecting pathogenic bacteria of pulmonary infection by a visualized gene chip, comprising the following steps: S1 determining the spectrum of pathogenic bacteria of pulmonary infection based on clinical practice; S2 making the detection target according to the specific gene of the bacteria; S3 designing general primers and probes S4 chip preparation; S5 target gene amplification; S6 chip hybridization and washing; S7 gene chip visual detection; S8 optimization conditions, establishment of methods; S9 clinical verification; S10 comparison with bacterial culture; Chip detection. Beneficial effects of the present invention: realize rapid, sensitive, and high-throughput detection of important pathogenic microorganisms of common clinical respiratory infection flora, provide evidence for clinical disease diagnosis and anti-infection treatment of acute and severe respiratory infectious diseases; provide emergency, prevention and control Provide effective and efficient screening means and methods.

The invention relates to an image quantization method, computer equipment and a storage medium. The method comprises the following steps: segmenting a medical image of a to-be-detected object to obtain a first class segmented image and a second class segmented image, wherein the first class segmented image comprises at least one first region of interest, and the second type segmented image comprises second regions of interest corresponding to the first regions of interest; determining feature data corresponding to each second region of interest according to the at least one first region of interest and the second region of interest corresponding to each first region of interest, wherein the feature data is used for representing the distribution condition of each second region of interest;and determining a quantized value corresponding to the medical image according to the feature data corresponding to each second region of interest and the clinical feature data of the to-be-detected object, wherein the clinical feature data is data obtained after clinical detection is conducted on the to-be-detected object, and the quantized value is used for indicating the severity degree of pulmonary infection on the medical image. The method can improve the detection precision.

The invention discloses a subglottic secretion drainage tracheal catheter, and particularly discloses a subglottic secretion drainage tracheal catheter belonging to the field of medical consumables. Through the subglottic secretion drainage tracheal catheter, the airway can be enclosed, the catheter can be fixed, positive pressure ventilation can be effectively finished, airway mucosa is protected, the comfort of a patient during subglottic secretion drainage is improved, upper respiratory tract secretions can be fundamentally prevented from entering the lower respiratory tract and the lung, and pulmonary infection is effectively prevented. The subglottic secretion drainage tracheal catheter comprises a catheter, an air bag, a joint, a gas tube and a suction tube, wherein the catheter is provided with a suction hole; the suction tube is communicated with the suction hole; one end of the suction tube is led out of the catheter; the air bag is provided with a storage groove. By adopting the subglottic secretion drainage tracheal catheter, the airway can be enclosed, and the airway mucosa is protected. Meanwhile, the complications of irritant severe cough, discomfort and the like during continuous subglottic secretion drainage are avoided, retentate and leakage on the air bag can be fundamentally prevented from entering the lower respiratory tract and the lung, and pulmonary infection is effectively prevented.

A method of using ionene polymers for the treatment or prevention of infections (e.g., pulmonary infections) in cystic fibrosis patients is provided. The method comprises administering to a mammal an effective amount of an ionene polymer to prophylactically or therapeutically treat infections associated with cystic fibrosis.

The invention relates to a scoliosis head circle gravity traction wheel chair. The structure of the invention comprises that: a wheel chair is provided with a traction counter weight; one end of a rope is connected with the counter weight and the other end of the rope is connected with a traction pulley; a supporting cross rod frame is arranged at the top of the wheel chair; the front and back ends of a cross rod are provided with a traction pulley and a counter weight pulley respectively; one end of the rope reaches the traction pulley through the counter weight pulley; and the rope coming down from the traction wheel is connected with a traction head circle. The invention overcomes the drawback that the common traction device is a fixed device at bed head, is used only for the protrusion of intervertebral disc or vertebral collapse and causes bedsore, pulmonary infection, lung function decline, osteoporosis and so on, as well as other drawbacks. The wheel chair is specially used for treating scoliosis. A period of traction treatment before surgery can obviously improve the vital capacity of a patient with scoliosis and the flexibility of backbone so as to improve the curative effect and success rate of the scoliosis surgeries and prevent the problems such as the protrusion of intervertebral disc or vertebral collapse and causes bedsore, pulmonary infection, lung function decline and osteoporosis.

The invention relates to an ambroxol hydrochloride solution for inhalation and a preparation method thereof. Ambroxol hydrochloride is used as an active ingredient. The ambroxol hydrochloride solution belongs to a sterile inhalation preparation capable of being used for treating diseases such as bronchial asthma, chronic bronchitis, emphysema, pulmonary heart diseases, pulmonary infection and COPD (chronic obstructive pulmonary diseases).

The invention relates to a traditional Chinese medicinal composition for treating pulmonary infection, an oral fast dissolving membrane and a preparation method thereof, and belongs to the technical field of traditional Chinese medicinal preparations. The traditional Chinese medicinal composition comprises the following components in parts by weight: 15 to 30 parts of ephedra herb, 5 to 20 parts of Chinese thorowax roots, 5 to 10 parts of tangerine peel, 4 to 6 parts of oroxylum indicum, 6 to 12 parts of white mulberry roots-barks, 4 to 6 parts of cortex lycii, 5 to 10 parts of lonicera japonica, 6 to 10 parts of forsythia suspensa shells and 4 to 7 parts of gardenia. The medicament has better treatment effects on pulmonary infection, and is particularly suitable for children to take, and a dosage form thereof is convenient to take and carry.

The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacter cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.

The invention discloses a multifunctional water bed. The multifunctional water bed comprises a sleeve bag, a water tank, a heater, a water pump, a nozzle group, a controller, a motor and a temperature probe, wherein the sleeve bag is longitudinally separated into a left sleeve bag and a right sleeve bag; the temperature probe comprises a water temperature probe and a body temperature probe; a water discharging hole of the water tank is connected with the heater through a filter; the heater is connected with an inlet of the water pump; the controller is connected with the motor and the heater; the motor is connected with the water pump; the controller is connected with the water temperature probe and the body temperature probe respectively. With the adoption of the multifunctional water bed, a function that a patient can turn over automatically is realized; meanwhile, an automatic back percussion function from bottom to top and from inside to outside of a patient after a thoracic surgery and pulmonary infection is also realized, so that the labor intensity of nurses is greatly alleviated; meanwhile, the multifunctional water bed is a cooling water bed for a patient with high fever and is a heat-conducting treatment water bed, and has an adjunctive treatment effect on the patient.